Article Text

Download PDFPDF
Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with essential hypertension, does atenolol reduce cardiovascular morbidity or all cause mortality?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Cardiology ★★★★★☆☆


Embedded ImageData sources:

Cochrane Library, Medline, relevant textbooks, and researchers in hypertension.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) that assessed the effect of atenolol (as the sole first line drug in 1 of the treatment groups) on cardiovascular morbidity or mortality in patients with essential hypertension.

Embedded ImageOutcomes:

myocardial infarction (MI), stroke, cardiovascular mortality, and all cause mortality.


8 RCTs met the selection criteria. 2 major comparisons were made. Atenonol compared with placebo or with untreated controls (4 RCTs, n = 6825). Mean reduction in blood pressure (BP) …

View Full Text